8.78
+10.16%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Prothena Corporation
From its filings with the US Securities and Exchange Commission
Prothena Corporation is based in Dublin 2, Ireland and is incorporated in Ireland. Its shares trade on Nasdaq under the ticker PRTA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $9.7m and a net loss of $244.1m. At that date it held total assets of $326.8m and shareholders' equity of $280.5m. By business, Collaboration revenue brought in 99.5% of revenue, followed by Revenue from license and intellectual property at 0.5%.
Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.
Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery.
The Company was formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012, and currently trade on The Nasdaq Global Select Market.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Dec 2012
- Employees
- 67
- Website
- prothena.com ↗
- Head office
- 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, L2, D02 VK60
- Incorporated in
- L2
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Daniel WelchIndependent Chairman of the Board$2.7m
- Dr. Lars EkmanChairman Emeritus$304,851
- Dr. Gene KinneyPresident, Chief Executive Officer, Director, since 2012$7.2m
- Mr. Tran NguyenChief Financial Officer, Chief Strategy Officer$2.6m
- Mr. Brandon SmithChief Operating Officer$2.5m
- Ms. Karin WalkerChief Accounting Officer
- Dr. Wagner ZagoChief Scientific Officer$2.4m
- Dr. Chad SwansonChief Development Officer
- Mr. Michael MalecekChief Legal Officer, Company Secretary$1.2m
- Ms. Paula CobbIndependent Director$304,346
- Mr. Richard CollierIndependent Director$302,641
- Mr. Shane CookeIndependent Director$309,958
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 63
- Social
- 51
- Governance
- 57
- Women in the workforce
- 63%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Prothena Corporation is a leading biotechnology company that specializes in the discovery and development of novel therapies for neurodegenerative diseases. Their strengths include:
Weaknesses
- Despite its strengths, Prothena Corporation also faces certain weaknesses that could hinder its growth and success. These weaknesses include:
Opportunities
- Prothena Corporation operates in an industry with several opportunities that can drive its growth and profitability. These opportunities include:
Threats
- Prothena Corporation faces various threats that could impede its progress and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.